Drug Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Drug Name hu14.18-IL2
Trade Name
Synonyms Lorukafusp alfa|EMD-273063|EMD 273063|APN301|APN-301|APN 301
Drug Descriptions

Hu14.18-IL2 (Lorukafusp alfa) is a fusion protein comprised of a monoclonal antibody targeting the GD2 disialoganglioside linked to interleukin-2, which may inhibit growth of and induce an immune response against GD2-expressing tumors (PMID: 22844125, PMID: 20921469, PMID: 30073390).

CAS Registry Number 2131168-99-3
NCIT ID C162537


  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"


  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Therapy Name Drugs Efficacy Evidence Clinical Trials
hu14.18-IL2 hu14.18-IL2 0 2
hu14.18-IL2 + Ipilimumab + Nivolumab Ipilimumab Nivolumab hu14.18-IL2 0 1
hu14.18-IL2 + Nivolumab Nivolumab hu14.18-IL2 0 1

Additional content available in CKB BOOST